Physician profile
Ashley Hoffman
NPI 1770855256
$12,736.32
in general payments reported to CMS, 2019-2025
26 companies · $2,544 in 2025
The $2,544 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $2,752 · 2023: $4,445 · 2024: $2,874 · 2025: $2,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,418 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,418.07 |
| Education | $444.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,489.87 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,306.42 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,198.15 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $879.68 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $839.46 | 2022-2025 | |
| Ucb, INC. | $772.68 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $750.20 | 2022-2025 | |
| Amgen INC. | $727.09 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $646.84 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $533.59 | 2021-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $470.00 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $387.15 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $371.64 | 2022-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $349.65 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $196.98 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $191.00 | 2022-2024 | Adbry |
| Dermavant Sciences, INC. | $164.86 | 2022-2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.30 | 2023-2024 | Cyltezo, Spevigo |
| Janssen Scientific Affairs, LLC | $113.65 | 2022 | |
| Organon LLC | $69.91 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $44.49 | 2023-2024 | Idacio |
| Sandoz INC. | $29.80 | 2024 | Hyrimoz |
| Merz North America, INC. | $23.39 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.97 | 2024 | Ycanth |
| Biofrontera INC. | $19.51 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.